Cargando…

Should Studies of Diabetes Treatment Stratification Correct for Baseline HbA1c?

AIMS: Baseline HbA1c is a major predictor of response to glucose lowering therapy and therefore a potential confounder in studies aiming to identify other predictors. However, baseline adjustment may introduce error if the association between baseline HbA1c and response is substantially due to measu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jones, Angus G., Lonergan, Mike, Henley, William E., Pearson, Ewan R., Hattersley, Andrew T., Shields, Beverley M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4822872/ https://www.ncbi.nlm.nih.gov/pubmed/27050911 http://dx.doi.org/10.1371/journal.pone.0152428

Ejemplares similares

What to do with diabetes therapies when HbA1c lowering is inadequate: add, switch, or continue? A MASTERMIND study
por: McGovern, Andrew P., et al.
Publicado: (2019)

Correction to: The impact of population-level HbA(1c) screening on reducing diabetes diagnostic delay in middle-aged adults: a UK Biobank analysis
por: Young, Katherine G., et al.
Publicado: (2023)

Evaluating associations between the benefits and risks of drug therapy in type 2 diabetes: a joint modeling approach
por: Dennis, John M, et al.
Publicado: (2018)

Patient stratification for determining optimal second and third line therapy for type 2 diabetes: the TriMaster study
por: Shields, Beverley M, et al.
Publicado: (2023)

The impact of population-level HbA(1c) screening on reducing diabetes diagnostic delay in middle-aged adults: a UK Biobank analysis
por: Young, Katherine G., et al.
Publicado: (2022)

Choice of HbA1c threshold for identifying individuals at high risk of type 2 diabetes and implications for diabetes prevention programmes: a cohort study
por: Rodgers, Lauren R., et al.
Publicado: (2021)

Cohort profile for the MASTERMIND study: using the Clinical Practice Research Datalink (CPRD) to investigate stratification of response to treatment in patients with type 2 diabetes
por: Rodgers, Lauren R, et al.
Publicado: (2017)

Identifying Good Responders to Glucose Lowering Therapy in Type 2 Diabetes: Implications for Stratified Medicine
por: Jones, Angus G., et al.
Publicado: (2014)

Use of HbA1c in the Identification of Patients with Hyperglycaemia Caused by a Glucokinase Mutation: Observational Case Control Studies
por: Steele, Anna M., et al.
Publicado: (2013)

TriMaster: randomised double-blind crossover study of a DPP4 inhibitor, SGLT2 inhibitor and thiazolidinedione as second-line or third-line therapy in patients with type 2 diabetes who have suboptimal glycaemic control on metformin treatment with or without a sulfonylurea—a MASTERMIND study protocol
por: Angwin, Catherine, et al.
Publicado: (2020)

Disease progression and treatment response in data-driven subgroups of type 2 diabetes compared with models based on simple clinical features: an analysis using clinical trial data
por: Dennis, John M, et al.
Publicado: (2019)

HbA1c performs well in monitoring glucose control even in populations with high prevalence of medical conditions that may alter its reliability: the OPTIMAL observational multicenter study
por: Niwaha, Anxious J, et al.
Publicado: (2021)

Effect of once‐weekly dulaglutide on glycated haemoglobin (HbA1c) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c
por: Gallwitz, Baptist, et al.
Publicado: (2017)

Measurement of HbA(1c) and HbA(2) by Capillarys 2 Flex Piercing HbA(1c) programme for simultaneous management of diabetes and screening for thalassemia
por: Ke, Peifeng, et al.
Publicado: (2017)

Change in HbA(1c) Across the Baseline HbA(1c) Range in Type 2 Diabetes Patients Receiving Once-Weekly Dulaglutide Versus Other Incretin Agents
por: Gentilella, Raffaella, et al.
Publicado: (2019)

Time trends in prescribing of type 2 diabetes drugs, glycaemic response and risk factors: A retrospective analysis of primary care data, 2010–2017
por: Dennis, John M., et al.
Publicado: (2019)

The True Value of HbA1c as a Predictor of Diabetic Complications: Simulations of HbA1c Variables
por: Lind, Marcus, et al.
Publicado: (2009)

Standardization of the HbA(2) Assay
por: Paleari, Renata, et al.
Publicado: (2018)

Significantly High HbA(1c) in Diabetic Patient with Hb J: Case Report
por: Wan Nik, Wan Nor Fazila Hafizan, et al.
Publicado: (2022)

Influence of Baseline HbA1c and Antiplatelet Therapy on 1-Year Vein Graft Outcome
por: Zhu, Yunpeng, et al.
Publicado: (2022)

Response to Comment on: Besser et al. Lessons From the Mixed-Meal Tolerance Test: Use of 90-Minute and Fasting C-Peptide in Pediatric Diabetes. Diabetes Care 2013;36:195–201
por: Shields, Beverley M., et al.
Publicado: (2013)

Slope of change in HbA(1c) from baseline with empagliflozin compared with sitagliptin or glimepiride in patients with type 2 diabetes
por: DeFronzo, Ralph A., et al.
Publicado: (2018)

Cost-effectiveness analysis for HbA1c test intervals to screen patients with type 2 diabetes based on risk stratification
por: Ohde, Sachiko, et al.
Publicado: (2021)

HbA(1c) and the Prediction of Type 2 Diabetes in Children and Adults
por: Vijayakumar, Pavithra, et al.
Publicado: (2017)

Patient preference for second and third line therapies in type 2 diabetes: a prespecified secondary endpoint of the TriMaster study
por: Shields, Beverley M, et al.
Publicado: (2023)

Persistent C‐peptide is associated with reduced hypoglycaemia but not HbA(1c) in adults with longstanding Type 1 diabetes: evidence for lack of intensive treatment in UK clinical practice?
por: Marren, S. M., et al.
Publicado: (2019)

Development and validation of multivariable clinical diagnostic models to identify type 1 diabetes requiring rapid insulin therapy in adults aged 18–50 years
por: Lynam, Anita, et al.
Publicado: (2019)

Efficacy and Safety of Dulaglutide by Baseline HbA1c in Chinese Patients with Type 2 Diabetes: A Post Hoc Analysis
por: Yu, Miao, et al.
Publicado: (2020)

Association of Diabetes and HbA(1c) Levels With Gastrointestinal Manifestations
por: Tseng, Ping-Huei, et al.
Publicado: (2012)

An Emerging Diabetes Mellitus Diagnosis Modality: HbA(1c)
por: Seo, Hyun-Ae, et al.
Publicado: (2012)

The Utility of HbA1c as a Diagnostic Criterion of Diabetes
por: Kim, Hee-Jung, et al.
Publicado: (2011)

Glycated haemoglobin (HbA(1c)) for postmortem diagnosis of diabetes
por: Lepik, Delia, et al.
Publicado: (2018)

HbA1c and retinal sensitivity in diabetics using microperimetry
por: Sharanjeet-Kaur, et al.
Publicado: (2019)

Is HbA1c an ideal biomarker of well-controlled diabetes?
por: Kaiafa, Georgia, et al.
Publicado: (2020)

HbA(1c): The lower the better?
por: Araki, Eiichi, et al.
Publicado: (2011)

Visit-to-visit HbA1c variability is inversely related to baroreflex sensitivity independently of HbA1c value in type 2 diabetes
por: Matsutani, Daisuke, et al.
Publicado: (2018)

Haemoglobin J-Baltimore can be detected by HbA(1c) electropherogram but with underestimated HbA(1c) value
por: Brunel, Valéry, et al.
Publicado: (2016)

Costs and Treatment Pathways for Type 2 Diabetes in the UK: A Mastermind Cohort Study
por: Eibich, Peter, et al.
Publicado: (2017)

Are the Same Clinical Risk Factors Relevant for Incident Diabetes Defined by Treatment, Fasting Plasma Glucose, and HbA(1c)?
por: Balkau, Beverley, et al.
Publicado: (2011)

Apparent subadditivity of the efficacy of initial combination treatments for type 2 diabetes is largely explained by the impact of baseline HbA1c on efficacy
por: Polidori, D., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_k4vuvr0lnhmrmq0aod7fjopngj